Indeed, the peripheral administration of the anti-TNF-α Infliximab has previously been shown to restore glucose homeostasis of 8 weeks HFD-induced obesity and diabetes (Araújo et al., 2007). This evidence concerns the gene TNF and obesity due to melanocortin 4 receptor deficiency.